BIIB Stock Brushes Off Bull Note

Biogen also joined Behind The Seizure -- a group providing genetic testing to children under eight

Digital Content Manager
Jan 8, 2020 at 10:37 AM
facebook twitter linkedin


Biopharmaceutical concern Biogen Inc (NASDAQ:BIIB) is slightly lower today, despite joining Behind the Seizure, along with a number of other companies, which works to provide faster diagnosis to children under eight with epilepsy. In addition to this, RBC lifted its price target to $285 from $267, which is still a slight discount to last night's close. At last check, BIIB is down 0.4% at $289.03. 

Since its late-October bull gap, the stock has been contained by the $280 and $310 regions, with recent support emerging at the 60-day moving average. On the other hand, BIIB is pacing for its fifth straight loss and is down 10.7% year-over-year. 

Analysts are still cautious on the stock, with 17 in coverage giving it a "hold" or worse rating, compared to only seven calling it a "strong buy." Plus, the consensus 12-month target price of $303.29 is just a slim 5.7% premium to current levels. 

 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners